Drug Trial Radar · NCT06632600
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Apr 28, 2025
Primary completion
Jul 22, 2027
Study completion Jan 21, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.
Conditions
- Chagas Disease
Interventions
LXE408Drug
LXE408 administered by oral route
PlaceboDrug
Placebo administered by oral route
BenznidazoleDrug
Benznidazole administered by oral route (administered as standard of care)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 28 days versus placebo.Time frame: At Months 2, 4, and 6
Locations
22 sites in 4 countries. Site status is shown where the registry gives one.
Olive View UCLA Educ and Res Ins
Sylmar, California · Recruiting
University of Florida Shands
Gainesville, Florida · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Novartis Investigative Site
Caba, Argentina · Recruiting
Novartis Investigative Site
Corrientes, Argentina · Recruiting
Novartis Investigative Site
Formosa, Argentina · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina · Recruiting
Novartis Investigative Site
Montes Claros, Minas Gerais, Brazil · Recruiting
Novartis Investigative Site
Recife, Pernambuco, Brazil · Recruiting
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Novartis Investigative Site
São Caetano do Sul, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Bogotá, Colombia · Recruiting
Novartis Investigative Site
Bogotá, Colombia · Recruiting
Novartis Investigative Site
Floridablanca, Colombia · Recruiting
Novartis Investigative Site
San Gil, Colombia · Recruiting
Novartis Investigative Site
Barranquilla, Atlántico, Colombia · Recruiting
Novartis Investigative Site
Yopal, Casanare Department, Colombia · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.